Hypha Labs (OTCQB:FUNI) Sees State-by-State Psilocybin Reform Creating the Next Major Growth Opportunity

Rhea-AI Summary

Hypha Labs (OTCQB:FUNI), a biotechnology company focused on advanced mushroom production technologies, states that expanding state-level psilocybin programs in Oregon, Colorado, New Mexico and over two dozen other states may create long-term demand for scalable manufacturing infrastructure. The company is developing a patent-pending production platform targeting speed, consistency, scalability and economics for research, pharmaceutical and functional mushroom markets, positioning itself as an infrastructure and technology supplier to the emerging psychedelic industry.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company Believes Industry Is Following the Early Regulatory Path That Fueled the Cannabis Market

LAS VEGAS, NV / ACCESS Newswire / July 13, 2026 / Hypha Labs, Inc. (OTCQB:FUNI), a biotechnology company developing advanced mushroom production technologies, believes the rapidly expanding state-by-state adoption of psilocybin programs is creating a significant long-term opportunity for scalable manufacturing infrastructure.

With Oregon, Colorado, and New Mexico now operating statewide psilocybin programs and more than two dozen states considering medical, research, or decriminalization legislation, Hypha Labs believes the industry is following a regulatory path similar to the early days of cannabis.

"We believe the psychedelic industry is approaching an important inflection point," said Stone Douglass, Chief Executive Officer of Hypha Labs. "As therapeutic markets expand, demand for reliable, scalable mushroom production technology is expected to grow. Our focus is on building the infrastructure that can support that future."

Rather than developing pharmaceutical compounds, Hypha Labs is focused on its patent-pending mushroom production platform designed to improve the speed, consistency, scalability, and economics of mushroom cultivation for research, pharmaceutical, and functional mushroom applications.

"We believe the greatest long-term opportunity may lie in supplying the industry rather than competing within it," added Douglass. "As cannabis demonstrated, infrastructure and technology providers can play an essential role in the growth of an emerging market."

About Hypha Labs, Inc.

Hypha Labs, Inc. (OTCQB:FUNI) develops proprietary mushroom production technologies designed to improve the cultivation and commercialization of functional mushrooms and future psychedelic-derived compounds.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied. Please refer to the Company's public filings for additional information regarding these risks.

From time to time, the Company may post new material information on its website or through its social media profiles at the links below:

LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs

For more information about Hypha Labs visit
HyphaLabs.com

For the Company's current Investor Presentation please visit
www.HyphaLabs.com/deck

Contact

Hypha Labs, Inc.
702 744 0640
info@hyphalabs.com

SOURCE: Hypha Labs, Inc.

View the original press release on ACCESS Newswire

FAQ

What opportunity does Hypha Labs (OTCQB:FUNI) see in state-by-state psilocybin reform?

Hypha Labs sees state-by-state psilocybin reform as a significant long-term opportunity for scalable mushroom manufacturing infrastructure. According to Hypha Labs, expanding therapeutic and research markets may increase demand for reliable, scalable mushroom production technology serving psychedelic and functional mushroom applications.

How is Hypha Labs (FUNI) positioned in the growing psychedelic and mushroom market?

Hypha Labs focuses on supplying infrastructure and technology rather than developing pharmaceutical compounds. According to Hypha Labs, its patent-pending mushroom production platform aims to improve speed, consistency, scalability and economics of cultivation for research, pharmaceutical and functional mushroom markets.

What is unique about Hypha Labs’ mushroom production platform for investors in FUNI?

Hypha Labs is developing a patent-pending mushroom production platform designed to enhance speed, consistency, scalability and economics of cultivation. According to Hypha Labs, this technology targets research, pharmaceutical and functional mushroom uses, aiming to support industry-wide commercialization and growth as psilocybin programs expand.

Why does Hypha Labs compare psilocybin regulation to the early cannabis market?

Hypha Labs believes psilocybin is following a regulatory path similar to early cannabis, with state-by-state adoption. According to Hypha Labs, this pattern suggests infrastructure and technology providers could become important, as happened in the cannabis sector’s growth phase.

What is Hypha Labs’ core business focus and strategy in 2026?

Hypha Labs’ core focus is developing proprietary mushroom production technologies instead of direct pharmaceutical drug development. According to Hypha Labs, the strategy centers on supplying scalable cultivation infrastructure to support functional mushroom markets and potential future psychedelic-derived compound commercialization.